Clinical trial
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular…
NCT00473330 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00473330 |
|---|---|
| Title | A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) |
| Official title | A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus |
| Acronym | RISE |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Macular Edema |
| Intervention type | Drug |
| Interventions | Ranibizumab, Sham injection |
| Enrollment | 377 |
| Start date | Jun 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2012 |
| First posted | May 15, 2007 |
| Last update posted | Apr 17, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: